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Background: Mesenchymal stem cell (MSC) transplantation has emerged as a promising therapy for liver fibrosis.
Issues concerning poor MSC survival and engraftment in the fibrotic liver still persist and warrant development of a
strategy to increase MSC potency for liver repair. The present study was designed to examine a synergistic role for
Interleukin-6 (IL-6) and MSCs therapy in the recovery of carbon tetrachloride (CCl4) induced injured hepatocytes
in vitro and in vivo.
Methods: Injury was induced through 3 mM and 5 mM CCl4 treatment of cultured hepatocytes while fibrotic
mouse model was established by injecting 0.5 ml/kg CCl4 followed by treatment with IL-6 and MSCs. Effect of
MSCs and IL-6 treatment on injured hepatocytes was determined by lactate dehydrogenase release, RT-PCR for
(Bax, Bcl-xl, Caspase3, Cytokeratin 8, NFκB, TNF-α) and annexin V apoptotic detection. Analysis of MSC and IL-6
treatment on liver fibrosis was measured by histopathology, PAS, TUNEL and Sirius red staining, RT-PCR, and liver
function tests for Bilirubin and Alkaline Phosphatase (ALP).
Results: A significant reduction in LDH release and apoptosis was observed in hepatocytes treated with a
combination of MSCs and IL-6 concomitant with upregulation of anti-apoptotic gene Bcl-xl expression and down
regulation of bax, caspase3, NFκB and TNF-α. Adoptive transfer of MSCs in fibrotic liver pretreated with IL-6 resulted
increased MSCs homing and reduced fibrosis and apoptosis. Hepatic functional assessment demonstrated reduced
serum levels of Bilirubin and ALP.
Conclusion: Pretreatment of fibrotic liver with IL-6 improves hepatic microenvironment and primes it for MSC
transplantation leading to enhanced reduction of liver injury after fibrosis. Synergistic effect of IL-6 and MSCs seems
a favored therapeutic option in attenuation of liver apoptosis and fibrosis accompanied by improved liver function.
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Mesenchymal stem cells (MSCs) are multipotent adult
stem cells present in bone marrow, adipose tissue and
cord blood and have emerged recently as an attractive
candidate for liver repair. MSCs have been shown to form
functional hepatocytes in vitro [1,2] and possess the ability
to secrete soluble factors stimulating endogenous paren-
chymal cells to support tissue recovery [3,4]. Moreover,
MSC transplantation in a liver fibrosis model can reduce
fibrosis [5] and restore depleted hepatic function [5-7].* Correspondence: riazuddin@aimrc.org
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reproduction in any medium, provided the orSimilarly, treatment with bone marrow derived stem cells
can attenuate liver fibrosis by preservation of metallo-
proteinase levels in fibrotic liver [8].
During the course of liver fibrosis different cytokines,
chemokines and growth factors are released as part of the
inflammatory response. Among these secreted factors,
IL-6 is a pleiotropic cytokine involved in inflammatory
pathways, hematopoiesis and immune regulation. Recent
evidence implicates IL-6 in survival and regeneration of
hepatocytes through Nuclear Factor-kappa B (NF-κB) sig-
nal transduction and the Ras–MAPK (mitogen-activated
protein kinase) pathway [9]. Increased liver injury was ob-
served on CCl4 induction in IL-6−/− mice due to TNF-α
production showing the role of IL-6 downstream of TNF-αd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tenuated through IL-6 and many of the antiapoptotic
genes like Bcl-xl, Bcl-2 and FLIP are upregulated [11].
Exogenous IL-6 treatment corrected the defects in cell
proliferation in IL-6−/− mice showing its role as mito-
genic agent in liver regeneration after partial hepatec-
tomy [12,13]. In addition, positive effects of IL-6 on
proliferation and DNA synthesis have been observed on
primary hepatocyte cultures [14].
Accumulating evidence suggests that MSCs can home
and migrate to injured liver but are unable to differentiate
into hepatocytes rather promoting fibrogenesis in vivo
[15,16]. Moreover, issues with MSC engraftment and long
term survival within hostile liver microenvironment may
also adversely affect the outcome of MSC therapy for liver
repair. The aim of the present study was to enhance MSC
potential for hepatic repair after CCl4 induced liver injury
in mouse. We hypothesized that priming hepatic micro-
environment with IL-6 would allow an increase in MSC
mediated regenerative response by imparting protection
to existing hepatocytes. We demonstrate that IL-6 and
MSCs synergistically enhance hepatic repair, reduce liver
fibrosis and improve overall hepatic function compared to
either of the treatments alone.
Materials and methods
Animals
The investigation conforms to the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85–23, revised
1985). All animals were treated according to procedures
approved by the Institutional Review Board (IRB) at the
National Center of Excellence in Molecular Biology, Lahore,
Pakistan.
Cell culture
Mesenchymal stem cells (MSCs) were isolated from tibias
and femora of 2 months old C57BL/6 mice (n=10)
according to their ability to adhere to plastic surface of a
culture flask and were cultured as described previously [17].
Hepatocyte isolation
Hepatocytes were isolated from C57BL/6 mice (n=20)
according to the two step perfusion method as described
previously [18]. Isolated hepatocytes were plated at a
concentration of 1 x 104 cells/cm2 in collagen coated plates
(Becton Dickinson, USA) in RPMI 1640 medium (Sigma
Aldrich, USA) supplemented with 100 ug/ml streptomycin
(MP Biomedicals, USA), 100 units/ml penicillin (MP
Biomedicals, USA) and 10% fetal bovine serum (Sigma
Aldrich, USA) in a humidified incubator at 5% CO2
and 37°C temperature. Medium was replaced after 3
and 24 hrs after seeding followed by various treatments.In vitro co-culture model
Hepatocytes were plated on a 6-well collagen coated plate
(Becton Dickinson, USA) at a concentration of 1 × 104
cells/cm2 and were subjected to injury with 3 mM and
5 mM Carbon tetrachloride (CCl4, Merck, Germany)
dissolved in DMSO (Merck, Germany) [19,20]. Injured he-
patocytes were treated with Interleukin-6 [(IL-6, 10 ng/ml)
(Sigma Aldrich, USA)] for 24 hours followed by MSCs
administration in a transwell culture system with
Dulbecco's Modified Eagle Medium (DMEM) (sigma)
medium having 10% FBS, 100 U/ml penicillin and
100 μg/ml streptomycin. Hepatocyctes were divided into 5
groups as, non-treated, CCl4, IL-6, MSCs and MSCs + IL-6
treated hepatocytes. Co-culture lasted for 24 hours and
hepatocytes were harvested for RNA extraction, apop-
tosis analysis and LDH cytotoxicity tests [21].LDH Assay
Cytotoxicity was analyzed through Lactate dehydrogenase
assay according to manufacturer’s protocol (Sigma Aldrich,
USA) in hepatocytes co-cultured with MSCs in the pre-
sence or absence of IL-6. Normal, CCl4 and IL-6 treated
hepatocytes were used as controls. Assay was run in
triplicate for each sample and absorbance was measured
at 490nm [22].Apoptosis
FITC-Annexin V kit (Abcam, USA) was used for detection
of apoptosis in all of the above mentioned in vitro groups
24 hours after co-culture. Cells were incubated with
Annexin-V for 15 minutes, fixed in 2% paraformaldehyde
and stained with DAPI (MP Biomedicals, USA).
Apoptosis was estimated on frozen liver sections of con-
trol and treatment groups by TUNEL assay kit (Millipore,
USA). Sections were fixed by 4% Paraformaldehyde and
stained with TUNEL assay kit according to manufacturer’s
protocol. Three sections were selected for each mouse and
three mice per treatment.CCl4 induced fibrotic liver model
Female C57BL/6 mice (6–8 weeks old) were subjected to
liver fibrosis by injecting 1 ml/kg CCl4 (Merck, Germany)
in olive oil (1:1) intraperitoneally for four weeks as previ-
ously described [23].In vivo IL-6 treatment
IL-6 (Sigma Aldrich, USA) was administered at a dose
of 100μg/kg intraperitonealy 24 and 48 hours after com-
pletion of 4 week CCl4 treatment. Mice were divided into
five groups i.e. non-treated, CCl4, IL-6, MSCs and MSCs +
IL-6 treated mice with n=10 animals in each group.
Table 1 Primer sequences
Gene Sequence Product size
Bax (F) TGGAGATGAACTGGACAGCA 182
Bax (R) CAAAGTAGAAGAGGGCAACCAC
Bcl-xl (F) TTCGGGATGGAGTAAACTGG 150
Bcl-xl (R) AAGGCTCTAGGTGGTCATTCAG
Albumin (F) GCTGTAGTGGATCCCTGGTG 196
Albumin (R) GCTGTAGCCTTGGGCTTG
Cytokeratin-8 (F) CTCACTAGCCCTGGCTTCAG 232
Cytokeratin-8 (R) ACAGCTGTCTCCCCGTGA
Caspase3 (F) TGTCATCTCGCTCTGGTACG 220
Caspase 3 (R) AAATGACCCCTTCATCACCA
NF-κB (F) GCACCTGTTCCAAAGAGCAC 200
NF-κB (R) GTGGAGTGAGACATGGACACAC
TNF-α (F) ACGGCATGGATCTCAAAGAC 162
TNF-α (R) GGAGGTTGACTTTCTCCTGGTA
βactin (F) GCTGTGTTGTCCCTGTATGC 106
βactin (R) GAGCGCGTAACCCTCATAGA
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MSCs were labeled with PKH-26 fluorescent cell linker
dye (Sigma Aldrich, USA) for their detection in the liver
post transplantation as shown previously [23]. MSCs + IL-6
groups received MSC transplantation 4 hours after com-
pletion of IL-6 injections. Anesthesia was induced and ab-
domen was neatly cut below diaphragm. After exposing
liver, approximately 106 cells/ml were transplanted directly
in to liver lobes at three lateral and two median sites with
a 30 G syringe.
Periodic acid schiff (PAS) stain
Periodic acid schiff [(PAS) (Sigma Aldrich, USA)] stain-
ing was performed for the estimation of glycogen storage
levels in sections from all animal groups 30 days after
MSCs and IL-6 treatment. After hydrating, paraffin sec-
tions were incubated in periodic acid for 5 minutes
followed by staining with Schiffs reagent for 15 minutes
and finally hematoxylin staining. Sections from three
animals for each group and three sections per treatment
were analyzed.
Sirius red
Sirius red staining provided assessment of the collagen de-
position in CCl4 injured and treated liver sections 30 days
after MSCs and IL-6 treatment. Nuclei were stained with
hemotoxylin (Sigma Aldrich, USA) and then picro-sirius
red stain (Direct red 80, Sigma) was applied for 1 hour.
Gene expression
Total RNA was extracted from injured and treated cells and
also from liver tissues samples using TRIZOL (Invitrogen,
USA). cDNA synthesis was carried out from 1 μg of RNA
sample using M-MLV reverse transcriptase (Invitrogen,
USA). For analysis of gene expression in MSCs after vari-
ous treatments, real time RT-PCR was carried out using
SYBR Green PCR Super Mix (BioRad, USA), 8 mM of
each primer and 100–500 ng/ml of template cDNA on
BioRad System iQ5. The relative ratio and standard devi-
ation between the normal and treated samples were calcu-
lated using the comparative Ct method (DD Ct value), as
recommended by the BioRad iQ5system. The expression
of Bax, Bcl-xl, albumin, caspase-3, cytokeratin-8, NFκB,
TNF-α was estimated by using Image J software. βactin
was used as internal control. All primer sequences have
been mentioned in Table 1.
Biochemical tests
Blood samples were taken from all experimental groups
30 days after treatment with MSCs and IL-6. Serum was
isolated and the amount of bilirubin (Diazyme Europe,
Gmbh) and alkaline phosphatase (Bioassay System, USA)
was estimated using commercial kits according to the
manufacturer’s protocol.Statistical analysis
Quantitative data was obtained from 3 slides from each
animal in different experimental groups for Sirius red
staining and were expressed as means ± SEM. Analysis
for percentage of fibrosis between groups was performed
by one-way ANOVA (p value of less than 0.05 was con-
sidered statistically significant) with bonferroni post-hoc
test. Data from10 animals/group was analyzed for biliru-
bin and ALP.
Results
In vitro hepatocyte injury model
Hepatocytes were exposed to different concentrations
of CCl4 i.e. 3 mM and 5 mM in medium for 2, 4 and
6 hours. Expression of apoptotic markers such as Bax,
and caspase-3 was significantly upregulated in 6 hours
group while Bcl-xl was downregulated as measured by RT-
PCR. Similarly, hepatic markers albumin and cytokeratin-8
were decreased with increase in CCl4 concentration and
duration of treatment (Figure 1A). Concurrently, level
of cytotoxicity as measured by LDH assay was signifi-
cantly higher 6 hours after 5 mM CCl4 treatment
(Figure 1B). Therefore, 5 mM CCl4 concentration for
6 hours was used in subsequent experiments with
in vitro cultured hepatocytes.
Enhanced hepatocyte protection in vitro after MSCs + IL-6
treatment
Hepatocytes were subjected to CCl4 treatment (5 mM
for 6 hours) followed by treatment with IL-6 for 24 hours.
At the end of IL-6 treatment, MSCs were co-cultured with
hepatocytes in a transwell system with or without IL-6.
Figure 1 In vitro hepatocyte injury model. A) Gene expression analysis of hepatic (Albumin, Cytokeratin-8), apoptotic (Bax, caspase-3) and anti-apoptotic
(Bcl-xl) markers after 3 mM and 5 mM CCl4 treatment is dose and time dependent as measured by RT-PCR (n=3). B) LDH (%) release in hepatocytes shows
maximum release after 5 mM CCl4 treatment for 6 hours (n=3).
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Non-treated, CCl4, IL-6, MSCs and MSCs + IL-6 treated
hepatocytes. Analysis of gene expression showed reduc-
tion in apoptotic markers such as Bax, Caspase-3, NFκB
and TNF-α in hepatocytes treated with MSCs and IL-6
alone compared to CCl4 group but a significant reduction
was observed after treatment with MSCs + IL-6 compared
to all other groups. Similarly, increased levels of anti apop-
totic marker Bcl-xl was observed after MSCs and IL-6
treatment alone but a greater reduction was observedFigure 2 Enhanced hepatocyte survival after co-culture with MSCs +
anti-apoptotic (Bcl-xl) markers in hepatocytes co-cultured with MSCs togeth
Image J (n=3). CCl4 vs MSCs + IL-6
ɸ p< 0.05, ɸ ɸ p< 0.01 and ɸ ɸ ɸ p< 0.001. C)
of apoptotic cells through annexin V staining (n=4). CCl4 vs IL-6 *p< 0.05, **p< 0
vs MSCs + IL-6 ɸ p< 0.05, ɸ ɸ p< 0.01 and ɸ ɸ ɸ p< 0.001, IL-6 vs MSCs + IL-6 ψp<
and δδδp< 0.001.after combined treatment of MSCs + IL-6 compared
to CCl4 treated hepatocytes (Figure 2A-B). Significant re-
duction in LDH levels was observed in IL-6 (32.5 ± 1.8%)
and MSCs (31.2 ± 1.5%) treated injured hepatocytes
(Figure 2C). However, treatment with MSCs + IL-6 showed
significant higher reduction (21.6 ± 1.6%) in cell injury than
any other treatment groups. Conversely, level of apop-
tosis as measured by Annexin-V staining was lower in
IL-6 (20.7 ± 1.4%) and MSCs (17.9 ± 0.9%) compared to
CCl4 (27.0 ± 2.0%). However, MSCs + IL-6 treatmentIL-6. A) Gene expression of apoptotic (Bax, caspase-3, NF-κB, TNF-α) and
er with IL-6. B) Gel band quantification of gene expressions through
LDH (%) release levels in control and treatment groups (n=4). D) Analysis
.01 and ***p< 0.001, CCl4 vs MSCs
#p< 0.05, ##p< 0.01 and ###p< 0.001, CCl4
0.05, ψψp< 0.01 and ψψψp< 0.001, MSCs vs MSCs + IL-6 δp< 0.05, δδp< 0.01
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staining compared to all other groups (Figure 2D).
Homing of transplanted MSCs
MSCs labeled with PKH 26 and DAPI were transplanted into
fibrotic livers in the presence or absence of IL-6. Increased
homing in fibrotic liver from MSCs + IL-6 (Figure 3A-C)
treatment group was observed as evidenced by increased
number of PKH-26/DAPI colabeled cells (31 ± 3.2
cells/mm2) compared to MSCs (20 ± 1.2 cells/mm2) only
transplantation group thus showing augmentation of MSC
homing and engraftment in fibrotic livers treated with IL-6.
Reduced fibrosis and apoptosis in CCl4 injured liver after
treatment with MSCs + IL-6
In order to demonstrate the combined treatment effect
of MSCs and IL-6 on fibrosis and apoptosis in fibrotic
liver, liver section from all treatment groups were
stained with Sirius red for fibrosis and TUNEL staining
for apoptosis detection. Mice treated with IL-6 and MSCs
alone showed reduction in fibrosis which was 3.1 ± 0.4%
and 2.1 ± 0.3% respectively compared to CCl4 treated ani-
mals (4.5 ± 0.1%) as evidenced by sirius red staining
(Figure 4A-F). However, significant reduction in fibrosis
was observed in MSCs + IL-6 treatment group (0.9 ±
0.2%) compared to all other groups. Conversely, TUNEL+
cells were reduced in fibrotic liver after IL-6 (28 ± 0.9%)
and MSCs (20 ± 1.6%) compared to CCl4 (39 ± 0.5%)
treatments (Figure 4G-L). However, there was significant
reduction in TUNEL+ cells in MSCs + IL-6 (9 ± 1.5%)
group compared to all other groups.
Improved hepatocyte survival and function in vivo after
MSCs + IL-6 treatment
PAS staining of liver sections from all animal groups was
done to evaluate the effect of combined treatment of
MSCs and IL-6 on restoration of functional hepatocytes
in liver damaged by CCl4 treatment. It was demonstrated
that animals treated with MSCs + IL-6 showed highFigure 3 MSC homing in injured liver 30 days post transplantation. A
Transplantation. C) Injured liver with combined treatment (MSCs + IL-6). Mlevels of glycogen storage compared to MSCs, IL-6
and CCl4 treated groups as evidence by PAS staining
(Figure 5A-D). In addition, increased expression of
Bcl-xl was observed in livers treated with MSCs + IL-6
compared to groups treated with either MSCs or IL-6 and
CCl4 (Figure 5F). Similarly, expression levels of apoptotic
markers such as Bax, caspase-3, NF-κB and TNF-α dem-
onstrated significant reduction after combined MSCs +
IL-6 administration compared both treatment alone and
CCl4 treated groups (Figure 5E) providing evidence that
MSCs + IL-6 administration enhances glycogen storing
ability of hepatocytes, promotes survival and decreases
apoptotic signaling.Biochemical functions
To further evaluate the role of combined treatment with
MSCs and IL-6 on augmentation of liver function, serum
levels of Alkaline phosphatase (ALP) and Bilirubin were
analyzed in all treatment groups. Serum levels of ALP
were significantly lower in mice receiving combined
treatment with MSCs + IL-6 (208 units/L) compared to
treatment with IL-6 (450 units/L), MSCs (390 units/L)
and CCl4 (613 units/L) groups (Figure 6A). Similarly,
Bilirubin level in MSCs + IL-6 treated group was
0.4 mg/dl, which was significantly lower than IL-6
(0.83 mg/dl), MSCs (0.63 mg/dl) and CCl4 (1.17 mg/dl)
treatment groups (Figure 6B). Collectively, these results
indicate that combined treatment with MSCs and IL-6
results in higher recovery of hepatic function than either
of the treatment alone compared to CCl4 treated mice.Discussion
Liver fibrosis is a progressive disease that involves disrup-
tion of hepatic tissue architecture and accumulation of
extracellular matrix in response to pathological insults.
Hepatocyte apoptosis as a consequence of prolonged
liver disease is one of the hallmarks of liver fibrosis and
leads to development of a fibrotic scar [24]. Bone mar-
row derived mesenchymal stem cells (MSCs) have been) Quantification of transplanted MSCs (n=6). B) Injured liver with MSCs
SCs vs MSCs + IL-6 *p< 0.05, **p< 0.01 and ***p< 0.001.
Figure 4 Reduced fibrosis and apoptosis in injured liver treated with MSCs + IL-6. A: Normal, B: CCl4 injury, C: IL-6 treated, D: MSCs
transplanted, E: IL-6 + MSCs transplanted, F: Graphical presentation of collagen levels (n=). CCl4 vs IL-6 NS, CCl4 vs MSCs
#p< 0.05, ##p< 0.01 and
###p< 0.001, CCl4 vs MSCs + IL-6
ɸ p< 0.05, ɸ ɸ p< 0.01 and ɸ ɸ ɸ p< 0.001, IL-6 vs MSCs + IL-6 ψp< 0.05, ψψp< 0.01 and ψψψp< 0.001, MSCs vs MSCs + IL-6
δp< 0.05, δδp< 0.01 and δδδp< 0.001. G-L Estimation of apoptosis in control fibrotic liver and treatment groups through TUNEL Assay. G: Normal, H: CCl4
injury, I: IL-6 treated, J: MSCs transplanted, K: IL-6 + MSCs transplanted, L: Graphical presentation of apoptotic positive cells in different treatment groups
(n=). CCl4 vs IL-6 *p< 0.05, **p< 0.01 and ***p< 0.001, CCl4 vs MSCs
#p< 0.05, ##p< 0.01 and ###p< 0.001, CCl4 vs MSCs + IL-6
ɸ p< 0.05, ɸ ɸ p< 0.01
and ɸ ɸ ɸ p< 0.001, IL-6 vs MSCs + IL-6 ψp< 0.05, ψψp< 0.01 and ψψψp< 0.001, MSCs vs MSCs + IL-6 δp< 0.05, δδp< 0.01 and δδδp< 0.001.
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and in vivo [26] proclaiming them as possible source for
repair of damaged liver. However, recent reports indicate
poor survival and engraftment of MSCs in hostile hepatic
milieu [15,27]. There is a dire need of strategies that
protect hepatocytes against injury promoting liver micro-
environment for MSCs engraftment and survival. Therefore,
in the present study we combined MSC transplantation
for repair of fibrotic liver with IL-6 treatment with the
premise that IL-6 treatment will protect hepatocytesfrom fibrotic injury thereby priming MSCs engraftment
and survival.
A large number of studies have been conducted aimed
at protecting hepatocytes from pathological injury thereby
augmenting hepatic milieu and promoting repair. He-
patocyte protection from hypoxic injury was recently
demonstrated by treatment with methylene blue and
epimorphin in rats [28,29]. Similarly, treatment with dif-
ferent cytoprotective chemicals can protect hepatocytes
against toxic injury [30-32]. Alternatively, treatment
Figure 5 Increased glycogen storage and survival signaling in livers after treatment with MSCs + IL-6. PAS staining of liver section from
A) - CCl4, B) IL-6, C) MSCs, D) MSCs + IL-6 treated animals (n=). E) Gene expression analysis of bcl-xl, bax, caspase-3, NFκB, TNF-α as measured by
quantitative RT-PCR (n=). CCl4 vs MSCs + IL-6 *p< 0.05, **p< 0.01 and ***p< 0.001.
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injury can enhance hepatocyte survival by activation of
pro survival cascades. Preconditioning hepatocytes with
IL-6, a major regulator of hepatic regeneration, before
induction of injury promotes proliferation [13,33,34]
and has a protective effect against apoptosis [11], etha-
nol and TNF induced injuries [35]. Conversely, IL-6 −/−
mice display delayed weight recovery, defective DNA
synthesis post operative mortality and severe liver
fibrosis [36-38]. Exogenous administration of IL-6 inFigure 6 Liver function tests. A) Alkaline phosphatase in serum of all animal
IL-6 *p< 0.05, **p< 0.01 and ***p< 0.001, CCl4 vs MSCs
#p< 0.05, ##p< 0.01 and #
IL-6 vs MSCs + IL-6 ψp< 0.05, ψψp< 0.01 and ψψψp< 0.001, MSCs vs MSCs + IL-6IL-6 −/− mice enhanced DNA replication to the levels
seen in wild type mice [13,34]. Therefore, we sought to
augment fibrotic liver tissue with exogenous IL-6 treatment
with the premise that IL-6 administration will protect
existing hepatocytes from CCl4 induced injury. Increased
hepatocyte survival will prime the hepatic milieu for MSCs
engraftment and survival leading to increase hepatic repair.
Recent evidence shows that soluble factors produced
by bone marrow cells can functionally enhance hepato-
cytes in a co-culture system [21,39]. Conversely, IL-6groups B) Bilirubin serum levels in all animal groups (n= 10/group). CCl4 vs
##p< 0.001, CCl4 vs MSCs + IL-6
ɸ p< 0.05, ɸ ɸ p< 0.01 and ɸ ɸ ɸ p< 0.001,
δp< 0.05, δδp< 0.01 and δδδp< 0.001.
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determine whether combined treatment with IL-6 and
MSCs can protect hepatocytes against CCl4 injury. In-
creased survival was observed in hepatocytes pretreated
with IL-6 co-cultured with MSCs in response to CCl4
induced injury as evidenced by decreased expression of
pro apoptotic markers (BAX, Caspase-3, TNF-α NFκB)
and LDH activity (Figure 2). Interestingly, co-culture of
MSCs alone or IL-6 treatment did not result in a signifi-
cant increase in hepatocyte survival compared to the
combination of MSC co-culture with IL-6 treatment.
Therefore, combination of IL-6 and soluble factors
released by MSCs can result in significantly improved
hepatocyte survival against CCl4 induced fibrosis than
any other treatment modality.
Beneficial effect of combined MSC and IL-6 treatment
on hepatocyte survival in vitro was extended in vivo to
demonstrate that IL-6 can enhance hepatocyte survival
and improve hepatic milieu that would lead to increased
efficacy of MSC therapy for the repair of fibrotic liver.
Recent studies show that IL-6−/− mice demonstrate
hepatocyte apoptosis after treatment with ethanol em-
phasizing the role of IL-6 in liver protection against drug
induced hepatoxicity [35]. Moreover, IL-6 can exert an
antioxidant effect on hepatocytes by imparting protec-
tion against ROS while Bcl2 and Bcl-xl levels were
shown to increase in IL-6 dependent manner [11]. Im-
provement in hepatic environment by virtue of increased
hepatocyte protection by IL-6 administration against
CCl4 induced injury would enable enhanced MSC sur-
vival and hepatic repair. Concurrently, increased MSC
homing was observed in IL-6 treated fibrotic livers com-
pared to non-treated hepatic tissue (Figure 3) and was
associated with reduced fibrosis and apoptosis (Figure 4).
In addition, combined treatment of MSCs and IL-6
resulted in increased glycogen storing ability of livers
affected by CCl4 induced fibrosis in conjunction with
increased expression of Bcl-xl and decreased expression
of Bax, caspase-3, TNF-α and NFκB (Figure 5). Aug-
mented hepatic environment evidenced by increased
hepatocyte survival leads to increased MSCs survival
that significantly improved hepatic function demon-
strated by serum levels of ALP and Bilirubin (Figure 6).
Cell therapy remains an attractive therapeutic modality
for the treatment of liver fibrosis however, the efficacy
of bone marrow derived MSCs within the hostile liver
tissue remains a serious concern. MSCs have the ability
to promote hepatocyte survival via paracrine mediated
effects [21,39] and can differentiate into functional hepa-
tocytes. Therefore, augmenting MSC capability for liver
repair by enhancing liver tissue environment by IL-6
administration can lead to increased MSC homing and
engraftment. Increased MSC survival within fibrotic
liver pretreated with IL-6 leads to functional hepaticimprovement and may be a novel therapeutic strategy
for the treatment of liver fibrosis.
Conclusion
We have demonstrated that IL-6 administration can sig-
nificantly enhance the ability of MSCs to repair liver
after CCl4 induced fibrosis. IL-6 is one of the pleiotropic
inflammatory cytokines produced by the liver in response
to injury. Recent evidence shows that IL-6 can enhance
hepatocyte survival while IL-6 depleted mice have
enhanced liver fibrosis. Furthermore, studies demonstrat-
ing MSC therapy for repair of liver fibrosis has debatable
results warranting a new strategy to enhance the potential
of MSCs for repair of damaged liver. MSC transplantation
in fibrotic livers treated together with IL-6 results in-
creases MSC engraftment leading to improved hepatic
function. Therefore, we report here a clinically viable
therapeutic option combining IL-6 treatment with MSCs
transplantation for the treatment of fibrotic liver.
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